Your institution may have access to this item. Find your institution then sign in to continue.
Title
Silent running: the race to the clinic.
Abstract
The article reports on an investigation on the RNA interference, a technique for turning genes off which has sparked a flurry of biotechnology investment in the U.S. Alnylam Pharmaceuticals Inc. and Sirna Therapeutics Inc. are fighting over intellectual-property rights. The drug-delivery problem suggested that the technique's initial forays into the clinic have been aimed at diseases affecting the eye.